Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

吉西他滨 医学 伊布替尼 内科学 肿瘤科 安慰剂 中性粒细胞减少症 紫杉醇 化疗 胃肠病学 病理 白血病 替代医学 慢性淋巴细胞白血病
作者
Margaret A. Tempero,Do‐Youn Oh,Josep M. Tabernero,Michele Reni,Eric Van Cutsem,Andrew Eugene Hendifar,Dirk Waldschmidt,Naureen Starling,Jean‐Baptiste Bachet,Heung Moon Chang,Joan Maurel,Rocio García‐Carbonero,Sara Lonardi,Lisa M. Coussens,Lawrence H. Fong,L. Claire Tsao,George W. Cole,Danelle Frances James,Teresa Mercade Macarulla
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:32 (5): 600-608 被引量:118
标识
DOI:10.1016/j.annonc.2021.01.070
摘要

BACKGROUND: First-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) includes nab-paclitaxel/gemcitabine. Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumor activity through tumor microenvironment modulation. The safety and efficacy of first-line ibrutinib plus nab-paclitaxel/gemcitabine treatment in patients with PDAC were evaluated. PATIENTS AND METHODS: ). Primary endpoints were overall survival (OS) and investigator-assessed progression-free survival (PFS); overall response rate and safety were assessed. RESULTS: In total, 424 patients were randomized (ibrutinib arm, n = 211; placebo arm, n = 213). Baseline characteristics were balanced across arms. After a median follow-up of 25 months, there was no significant difference in OS between ibrutinib plus nab-paclitaxel/gemcitabine versus placebo plus nab-paclitaxel/gemcitabine (median of 9.7 versus 10.8 months; P = 0.3225). PFS was shorter for ibrutinib plus nab-paclitaxel/gemcitabine compared with placebo plus nab-paclitaxel/gemcitabine (median 5.3 versus 6.0 months; P < 0.0001). Overall response rates were 29% and 42%, respectively (P = 0.0058). Patients in the ibrutinib arm had less time on treatment and received lower cumulative doses for all agents compared with the placebo arm. The most common grade ≥3 adverse events for ibrutinib versus placebo arms included neutropenia (24% versus 35%), peripheral sensory neuropathy (17% versus 8%), and anemia (16% versus 17%). Primary reasons for any treatment discontinuation were disease progression and adverse events. CONCLUSIONS: Ibrutinib plus nab-paclitaxel/gemcitabine did not improve OS or PFS for patients with PDAC. Safety was consistent with known profiles for these agents.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
陈y完成签到,获得积分10
刚刚
ny66完成签到,获得积分10
1秒前
1秒前
ish168178发布了新的文献求助10
1秒前
寻123完成签到,获得积分10
2秒前
2秒前
2秒前
2秒前
2秒前
珍珠发布了新的文献求助30
2秒前
柒九发布了新的文献求助10
2秒前
2秒前
领导范儿的应助被绯红逍遥采纳,获得10
3秒前
3秒前
kris发布了新的文献求助10
3秒前
QDU的应助被嘟嘟嘟采纳,获得20
3秒前
支摇伽发布了新的文献求助10
3秒前
复嘟嘟完成签到,获得积分10
4秒前
Nole的应助被观的采纳,获得30
4秒前
DW的应助被瑞达采纳,获得10
4秒前
搜集达人的应助被张顺采纳,获得10
4秒前
义气的哈密瓜完成签到,获得积分10
5秒前
搜集达人的应助被Hello_Alina采纳,获得10
5秒前
小黄发布了新的文献求助10
5秒前
Celeste完成签到 ,获得积分10
5秒前
kipo完成签到 ,获得积分10
5秒前
王十七发布了新的文献求助10
5秒前
6秒前
wanci的应助被爽朗的小王同学采纳,获得10
6秒前
瓶子完成签到 ,获得积分10
6秒前
甜美无剑发布了新的文献求助10
6秒前
李健的小迷弟的应助被youyyuy采纳,获得10
7秒前
8秒前
彳亍完成签到,获得积分10
8秒前
9秒前
斯文败类的应助被王新涛采纳,获得10
9秒前
9秒前
2339822272发布了新的文献求助10
9秒前
我是谁的应助被小胖采纳,获得30
10秒前
充电宝的应助被云晓采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287